D.E. Shaw & Co
RARE icon

D.E. Shaw & Co’s Ultragenyx Pharmaceutical RARE Stock Holding History

D.E. Shaw & Co’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-10,000
Closed -$533K – 3708
2017
Q3 		$533K Hold
10,000
– – ﹤0.01% 2872
2017
Q2 		$621K Buy
+10,000
New +$602K ﹤0.01% 2704
2016
Q1 		– Sell
-24,000
Closed -$2.69M – 3717
2015
Q4 		$2.69M Sell
24,000
-10,000
-29% -$1,000K ﹤0.01% 1894
2015
Q3 		$3.27M Buy
34,000
+24,000
+240% +$2.75M ﹤0.01% 1716
2015
Q2 		$1.02M Buy
+10,000
New +$776K ﹤0.01% 2684

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

D.E. Shaw & Co's RARE Position: Q1 2026 in Review

D.E. Shaw & Co increased its Ultragenyx Pharmaceutical (RARE) stake by 266% in Q1 2026, buying an estimated $20.6M and bringing the position to 1,261,018 shares worth $26.4M. The position accounts for 0.02% of the portfolio, ranked #983.

D.E. Shaw & Co first reported a position in RARE in Q1 2015 and has held it in 36 quarters since. The position peaked at $99M in Q4 2020. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • D.E. Shaw & Co held 1,261,018 shares of Ultragenyx Pharmaceutical worth $26.4M as of Q1 2026.
  • D.E. Shaw & Co bought 916,255 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $20.6M.
  • Ultragenyx Pharmaceutical made up 0.02% of D.E. Shaw & Co's portfolio in Q1 2026, its #983 holding.
  • D.E. Shaw & Co first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 36 quarters since.
  • D.E. Shaw & Co's Ultragenyx Pharmaceutical position peaked at $99M in Q4 2020.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.